Premium
BCR‐ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia
Author(s) -
Lucas Claire M.,
Harris Robert J.,
Giannoudis Athina,
Knight Katy,
Watmough Sarah J.,
Clark Richard E.
Publication year - 2010
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2009.08066.x
Subject(s) - imatinib , breakpoint cluster region , tyrosine kinase , medicine , imatinib mesylate , cancer research , tyrosine kinase inhibitor , myeloid leukemia , flow cytometry , philadelphia chromosome , sunitinib , oncology , cancer , immunology , biology , chromosomal translocation , receptor , genetics , gene